Evaxion and ExpreS²ion partner to develop new CMV vaccine
Pharmaceutical Technology
DECEMBER 6, 2022
Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Based on the CMV vaccine’s clinical development stage at the time of sublicensing, Evaxion could also receive royalty payments from ExpreS 2 ion.
Let's personalize your content